T 588

a neuroprotective agent; structure given in first source

Also Known As:

1-(benzo(b)thiophen-5-yl)-2-(2-(N,N-diethylamino)ethoxy)ethanol hydrochloride; 1-benzothiophen-5-yl-2-(2-(diethylamino)ethoxy)ethanol hydrochloride; T-588; Benzo(b)thiophene-5-methanol, alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)-

Networked: 15 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ikeda, Ken: 4 articles (07/2007 - 03/2002)
2.	Watabe, Kazuhiko: 3 articles (07/2007 - 06/2003)
3.	Iwasaki, Yasuo: 3 articles (02/2004 - 03/2002)
4.	Ono, Satoshi: 3 articles (02/2004 - 03/2002)
5.	Nakagawa, Masaya: 2 articles (07/2007 - 06/2003)
6.	Kawazoe, Yoko: 2 articles (12/2005 - 06/2003)
7.	Ichikawa, Yasumitsu: 2 articles (02/2004 - 03/2002)
8.	Igarashi, Osamu: 2 articles (02/2004 - 03/2002)
9.	Kinoshita, Masao: 2 articles (06/2003 - 03/2002)
10.	Marubuchi, Shigeki: 2 articles (06/2003 - 03/2002)

Related Diseases

1.	Reperfusion Injury 06/30/2000 - "Addition of both T-588 and NGF resulted in complete protection against Ca(2+) reperfusion injury. " 06/30/2000 - "T-588 at 1-10 microM partially protected astrocytes against reperfusion injury after exposure to Ca(2+)-free medium or hydrogen peroxide. " 11/01/1999 - "Several drugs including T-588 and idebenone protect astrocytes against Ca(2+)-reperfusion injury. " 06/30/2000 - "The effect of T-588 on Ca(2+) reperfusion injury including apoptosis was inhibited by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor 2'-amino-3'-methoxyflavone (PD98059), but not by the phosphoinositide 3-kinase inhibitor wortmannin. "
2.	Facial Nerve Injuries 06/01/2003 - "We investigated whether orally administered T-588 can rescue injured motoneurons after facial nerve avulsion in adult rats. " 06/01/2003 - "These results indicate that oral administration of T-588 ameliorates the survival of injured motoneurons and supports their neuronal function after facial nerve avulsion in adult rats. " 06/01/2003 - "Oral administration of a neuroprotective compound T-588 prevents motoneuron degeneration after facial nerve avulsion in adult rats."
3.	Alzheimer Disease (Alzheimer's Disease) 03/06/2000 - "Clinical trials of T-588 are underway in patients with Alzheimer's disease. "
4.	Motor Neuron Disease (Primary Lateral Sclerosis) 06/01/2003 - "T-588 may have therapeutic potential in motoneuron injury or motor neuron diseases in humans." 03/01/2002 - "Our data showing T-588 has neurotrophic action on VSCC and suggests a potential use of T-588 in treating diseases that involve degeneration and death of spinal motor neurons, such as motor neuropathy and motor neuron disease." 02/01/2004 - "Our results showing in vivo neurotrophic activity of T-588 for motor neurons support the applicability of T-588 for the treatment of motor neuron diseases, such as amyotrophic lateral sclerosis and motor neuropathies." 12/01/2005 - "These results indicate that the gene transfer of GDNF, BDNF, TGFbeta2, and GIF and oral administration of T-588 may prevent the degeneration of motoneurons in adult humans with motoneuron injury and motor neuron diseases."
5.	Body Weight (Weight, Body) 06/01/2014 - "T-588 (3 and 5mg/kg body weight) did not affect nonadapted HVOR gains, and impaired both gain-up and gain-down HVOR adaptation. " 11/01/2002 - "We orally administered either the vehicle, or 10, 30, or 100 mg/kg body weight (BW) of T-588 24 hours before the laser application. "

Related Drugs and Biologics

1.	Nerve Growth Factor (NGF)
2.	Glial Cell Line-Derived Neurotrophic Factor (GDNF)
3.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
4.	Brain-Derived Neurotrophic Factor (BDNF)
5.	Nootropic Agents (Nootropics)
6.	Proteins (Proteins, Gene)
7.	Phosphotransferases (Kinase)
8.	Phosphatidylinositols (Phosphatidylinositol)
9.	Mitogens
10.	Hydrogen Peroxide (Hydroperoxide)

Related Therapies and Procedures

1.	Oral Administration
2.	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
3.	Radiotherapy
4.	Mastectomy (Mammectomy)
5.	Lasers (Laser)